BAY 11-7082

Catalog No.S2913 Synonyms: BAY 11-7821

BAY 11-7082 Chemical Structure

Molecular Weight(MW): 207.25

BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.

Size Price Stock Quantity  
In DMSO USD 120 In stock
USD 90 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

7 Customer Reviews

  • Immunofluorescence images of Ishikawa cells showing the increase in the nuclear colocalization of ERa (red) and p65 (green) after E2 incubation. Nuclear colocalization is yellow. Treatment with ICI 182,780, PDTC or Bay inhibited the nuclear localization of both ERa and p65. Blue, DAPI-stained nuclei. All pictures were obtained the same day using the same microscope settings. Original magnification 3200, bar =50 um. Arrows, cytoplasmic ERa and p65 staining. ICI, ICI 182,780; Bay, Bay 11-7082.

    Int J Cancer 2014 135(2), 282-94. BAY 11-7082 purchased from Selleck.

    The inhibition of IκBα phosphorylation by BAY11-7082 (10 µM) was confirmed using western blotting, and GAPDH was used as an internal reference.

    Cancer Lett, 2016, 378(2):131-41. BAY 11-7082 purchased from Selleck.

  • The effect of vaspin on TNF α -induced THP-1 cell adhesion to HAECS measured staining with VibrantDiO® Cell-Labeling Solution. The level of THP-1 cell adhesion to HAECs was measured at 4 hr after treatment with 25 -100 ng/mL vaspin in the presence or absence of 10 ng/mL TNF α . BAY11-7082 (10 uM, S2913, Selleckchem, USA), an inhibitor of NF- κ B, was used as a positive control.

    Cardiovasc Diabetol 2014 13, 41. BAY 11-7082 purchased from Selleck.

    J Neurochem, 2018, 144(6):780-790. BAY 11-7082 purchased from Selleck.

  • Shown are Western blot analysis of Wnt5a expression in HDPCs treated with TNF-a (n=3–4). The gene expression level was normalized to GAPDH (n = 3–6). HDPCs were preincubated with pyrrolidinedithiocarbamic acid (PDTC, an NF-κB inhibitor), BAY11-7082 (an NF-κB inhibitor), SP600125 (a JNK inhibitor), SB203580 (a p38 inhibitor), or U0126 (an ERK inhibitor) before treatment with TNF-a.

    J Biol Chem 2014 289(30), 21028-21039. BAY 11-7082 purchased from Selleck.

    The irradiated Beas-2B cells were further co-cultured with U937 cells for 24 h after irradiation. In some experiments, Beas-2B cells were pretreated with 10 μM of U0126, SB203580, or necrostatin-1 for 1 h before irradiation, U937 cells were pretreated with 10 μM BAY 11-7082 1 h prior to cell co-culture, or 1 μg/ml anti-TNF-a antibody, 2 μg/ml anti-IL-8 antibody,40 nM SB225002 were added to the medium in the cell co-culture period. ***P < 0.001 compared with the non-irradiation control. #P < 0.05 ##P < 0.01 compared with cor-responding -irradiated cells.

    Mutation Research, 2016, 789:1-8. BAY 11-7082 purchased from Selleck.

  • Reverse transcription-quantitative polymerase chain reaction assays revealed the effect of atorvastatin on visfatin-induced inflammation. Human coronary artery endothelial cells were incubated in the absence or presence of 50 ng/ml visfatin, with or without 50 nM FK866, 50 µM BAY11-0782 or 10 µM atorvastatin, for 24 h. (A) Atorvastatin downregulated visfatin-induced IL-6 gene expression (P-values from left to right vs. control: 0.0081, 0.0045, 0.0233 and 0.0057). (B) Atorvastatin decreased visfatin-induced IL-8 gene expression (P-values from left to right vs. control: 0.0096, 0.0037, 0.0043 and 0.0031). (C) Atorvastatin downregulated visfatin-induced IL-6 release (P-values from left to right vs. control: 0.0078, 0.0022, 0.0783 and 0.0382). (D) Atorvastatin inhibited visfatin-induced IL-8 release (P-values from left to right vs. control: 0.0094, 0.0032, 0.0039 and 0.0035). Significant differences were determined using Student's t-test; *P<0.05, **P<0.01 vs. visfatin control. IL-6, interleukin-6; IL-8, interleukin-8.

    Oncol Lett, 2016, 12(2):1438-1444. BAY 11-7082 purchased from Selleck.

Purity & Quality Control

Choose Selective IκB/IKK Inhibitors

Biological Activity

Description BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.
Targets
E2-conjugating enzymes [6]
(Cell-free assay)
IκBα phosphorylation [1]
(Tumor cells)
10 μM
In vitro

BAY 11-7082 completely and specifically abrogates NF-κB DNA binding, downregulating the NF-κB-inducible cytokine IL-6 and inducing apoptosis. [1] BAY 11-7082 (< 8 μM) is able to effectively inhibit both basal and TNFα stimulated NFκB luciferase activity in a dose dependent manner. BAY 11-7082 (8 μM) strongly inhibits the rate of proliferation in NCI-H1703 cells. [2] Bay 11-7082 (5 μM) rapidly and efficiently reduces the DNA binding of NF-kappaB in HTLV-I-infected T-cell lines and down-regulates the expression of the antiapoptotic gene, Bcl-x(L), whereas it has little effect on the DNA binding of another transcription factor, AP-1. Bay 11-7082-induced apoptosis of primary ATL cells is more prominent than that of normal peripheral blood mononuclear cells, and apoptosis of these cells is also associated with down-regulation of NF-kappaB activity. Bay 11-7082 (5 μM) selectively induces apoptosis of HTLV-I–infected T-cell lines associated with down-regulation of the expression of cyclin D1, cyclin D2, and Bcl-xL. [3] BAY 11-7082 (100 μM) prevents the nuclear translocation of p65 elicited by NMDA and the NMDA-induced increase of NF-κB binding in mouse hippocampal slices. BAY 11-7082 prevents NMDA toxicity occurring in CA1 region of hippocampal slices with 40% neuroprotection at 20 μM and 70% neuroprotection at 100 μM. [4] BAY 11-7082 at all concentrations tested significantly inhibits NF-κB p65 DNA-binding activity in adipose tissue, whereas in skeletal muscle, BAY 11-7082 at 50 μM and 100 μM significantly inhibits NF-κB p65 DNA-binding activity. BAY 11-7082 (100 μM) reduces IKK-β protein in human adipose tissue and skeletal muscle. BAY 11-7082 (100 μM) significantly decreases the release of TNF-α from adipose tissue, whereas the release of IL-6 and IL-8 is significantly inhibited at all concentrations of BAY 11-7082 tested. BAY 11-7082 (50 μM) significantly decreases the release of TNF-α, IL-6, and IL-8 in skeletal muscle. [5] BAY 11-7082 is also found to inactivate the E2-conjugating enzymes Ubc (ubiquitin conjugating) 13 and UbcH7 and the E3 ligase LUBAC (linear ubiquitin assembly complex), and thus induces B-cell lymphoma and leukaemic T-cell death. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HeLa M3nQVGZ2dmO2aX;uJGF{e2G7 M4PaV|ExyqEQvF2= NWTDO|RjOS53IHi= MWXhZo9tcXOqZYOgRnBCKGmwZIXj[YQhfXBicnXneYxifGmxbjDv[kBHViCjbnSgUW1RNToEoB?= NF\SeXEzPTd7N{SzOy=>
SiHa  M3;JWmZ2dmO2aX;uJGF{e2G7 M3:x[|ExyqEQvF2= MlL6NU42KGh? NESxcYxi[m:uaYPo[ZMhSlCDIHnu[JVk\WRidYCgdoVofWyjdHnvckBw\iCITjDhcoQhVU2SLUpCpC=> MV2yOVc6PzR|Nx?=
ARPE-19 NYq3fWtbTnWwY4Tpc44hSXO|YYm= M3i0[FEh|ryP NUO5VGl{OC53IHi= NEfZO|Z{fXCycnXzd4V{KFSJLXnu[JVk\WUEoFnMMVjDqHC{b33veIVzKGGldHn2ZZRqd25? NIrTSG8zPTV7M{CyPS=>
HCT116 MY\GeY5kfGmxbjDBd5NigQ>? NXL1WlJjPSEQvF2= NHrwdFkzKGh? M4S2PGROW09? NF;JW|lifHSnboXheIV{KHOrbIntZZJqdi2rbnT1Z4VlKGSxd37y[Yd2dGG2aX;uJI9nKGO7Y3zpckBFOQ>? NX35bnRIOjV2N{m3NlM>
HMECs MXHGeY5kfGmxbjDBd5NigQ>? MUS1xsDPxE1? NUT4[YxpOiCq NIHBcYVi[m:uaYPo[ZMhXE6ILd8xMYlv\HWlZXSgWmNCVS1zIHX4dJJme3Orb39CpC=> NW\abZZHOjVzOUOxNVY>
A549  Mn\TSpVv[3Srb36gRZN{[Xl? M33LelEx6oDLwsXN NGXxWmkyOiCq NGLKPJp{fXCycnXzd4V{KES4bD2zJIlv\HWlZXSgZYN1cX[jdHnvckBw\iCyNkW= NHHHPXYzPTF3NkiwNC=>
RAW 264.7 NVrxdHIzTnWwY4Tpc44hSXO|YYm= NHXOUYw2yqEQvF2= M4XvVFEhcA>? MVzpcohq[mm2czDUUmYu|rFiYX7kJGlNNTF{IIC0NEBxem:mdXP0bY9v NU[1N3BbOjVyMUm1Olc>
macrophages MoXnSpVv[3Srb36gRZN{[Xl? NHvUTng2KML3TR?= NV\OWlRUOyCq NETrSGJx[XK2aXHscJkh[myxY3vzJHlRTlNvaX7keYNm\CCneIDy[ZN{cW:wIH;mJIlPV1NiYX7kJGNQYC1{wrC= M3fqPFI1QTZ5OEm4
HUVECs NFXt[XdHfW6ldHnvckBCe3OjeR?= NYK5fHdmOy1|MDFOwG0> NUS0VXl{OSCq M{O2WZJm\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gcYlTNTF2NnGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M4TPdFI1QDZ|OU[1
HeLa  MULGeY5kfGmxbjDBd5NigQ>? NYLoVI95PcLizszN M1jwNlI1KGh? MkTSSG1UVw>? MXny[YR2[2W|IITo[UBi[3Srdnn0fUBw\iCWTl[t{tEheHKxbX;0[ZLDqA>? MUiyOFY2Pzd6Mx?=
A549 NH7ZUHBHfW6ldHnvckBCe3OjeR?= M2HBXVExKM7:TR?= NUXXNGFXOeLCiXi= NUTNWYJlcW6qaXLpeJMhfGinIHnuZ5Jm[XOnIH;mJJBpd3OyaH:tTe67Ss7zIHnuJHBCOTB|LXnu[oVkfGWmIHP1cJR2emW|wrC= NIPZVIQzPDZzMkS4PC=>
HUVEC NV3H[IxmTnWwY4Tpc44hSXO|YYm= NW\oeZJSOjBiwsXN MXuwMlUhcA>? Mn[wSG1UVw>? MUfwdoV3\W62czD0bIUhcW6mdXP0bY9vKG:oIFXBUUBmgHC{ZYPzbY9v M13MTFI1PTVzMkC5
A549RT-eto MVXBdI9xfG:|aYOgRZN{[Xl? NX\a[nBQOTEEoN88US=> NFX3cnAzPCCq NHe1VZNFVVOR NH[ybJJi[2OnbHXyZZRmeyCIRWLPMY1m\GmjdHXkJIFxd3C2b4Ppdy=> NUHZe5JOOjR3M{WwPFM>
THP-1  MUnGeY5kfGmxbjDBd5NigQ>? MVmwMlEwOcLizszN M4f3XVAvPSCq NVHpXFV{[WK{b3fheIV{KFSQRj5OtUB{\WO{ZYTpc44h[XNid3XscEBieyC2aHWgbY5kemWjc3XkJJNm[3KndHnvckBw\iCLTD22JIFv\CCLTD2x{tI> NH7SVZEzPDN5OEWzOi=>
SKCXCR2  Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3DRVMzKML3TR?= MnvUOFghcA>? NF3Kd|dl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHOrZ37p[olk[W62bIm= M{D0NFI1Ozd4N{S3
SKCXCR2  MojGSpVv[3Srb36gRZN{[Xl? NUP2TVBkOiEEtV2= NGXyfGo1QCCq Mn3KZoxw[2u|IITo[UBEYEOOMT3pcoR2[2WmIHPlcIwhcW64YYPpc44> MlqwNlQ{PzZ5NEe=
OVCXCR2 MYfGeY5kfGmxbjDBd5NigQ>? M4W3bFIhyrWP MXq0PEBp Mmn4Zoxw[2u|IITo[UBEYEOOMT3pcoR2[2WmIHPlcIwhcW64YYPpc44> Mn[1NlQ{PzZ5NEe=
DSCs  M4HTfmZ2dmO2aX;uJGF{e2G7 MlPpNk42KM7:TR?= M4TUNFAvPSCq M{myWJJmfmW{c3XzJJRp\SCnbnjhcoNmdWWwdDDv[kBES0x{L1PDVlIh\XiycnXzd4lwdiCxZjDEV2N{KGmwZIXj[YQh[nliSVytN|M> NYPzSnpQOjR|NESyOFA>
WPs MYDGeY5kfGmxbjDBd5NigQ>? M4DiUFI2KM7:TR?= MX21JI1qdg>? NFHxd2t{fXCycnXzd4V{KEGWUDDhcoQhfleIIIPlZ5JmfGmxbh?= MonUNlQ{OzF{MEe=
A549RT-eto MknBRZBweHSxc3nzJGF{e2G7 NVvXPYJDOTEEoN88US=> MX2yOEBp NGe3VoNi[2OnbHXyZZRmeyCIMUSg[Zh1emGldD3t[YRq[XSnZDDhdI9xfG:|aYOgZ49u[mmwZXSgeJJm[XSvZX70JJdqfGhiRkG0 MVyyOFIzODd{NR?=
A549RT-eto NWX4[YZtTnWwY4Tpc44hSXO|YYm= M3POUFExyqEQvF2= M2T6XlI1KGh? NUTjNYpy\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuczDv[kBPTi4QulKgZY5lKFBvZ4FCpC=> MoPBNlQzOjB5MkW=
FaDu MVHGeY5kfGmxbjDBd5NigQ>? MYKyJIg> MojtbY5pcWKrdIOgdFY2KGW6cILld5Nqd25iYX7kJIJtd2OtczDUUmbPuS2rbnT1Z4VlKFSZSWPUJIV5eHKnc4Ppc44> M{PXPFI1OjJyNkKy
IVD  MnrUSpVv[3Srb36gRZN{[Xl? NUf2bXVzOTEEoN88US=> MlLrN{Bl M4e2ZZJmfmW{c3XzJHRPTi4QsfMAl41m\GmjdHXkJJN2eHC{ZYPzbY9vKG:oIITo[UBlcXOlIH3heJJqgCCvYXPyc41wdGWldXzld{Bi\2e{ZXPhckBidmRiY3;scIFo\W5iSVm= M133[lI1OTd4OEC4
IVD  MU\GeY5kfGmxbjDBd5NigQ>? MUOxNOKh|ryP MX:zJIQ> Mk\tZYJzd2ejdHXzJHRPTi4QsfMAl4lv\HWlZXSgeZAuemWpdXzheIlwdiCxZjDBSGFOXFNvNDDhcoQhSUSDTWTTMVXDqA>? M2TJW|I1OTd4OEC4
iNKT MljBSpVv[3Srb36gRZN{[Xl? NHXsVlYyOC9zMECg{txO MXSwMlUhcA>? NHvzPI5qdmirYnn0d{B1cGViaX7keYN1cW:wIH;mJGEzSVJibWLORUBidmRib4To[ZIh\mGldH;y M4PTOVI1OTJ2NEWz
PC-3 M2D0T2Z2dmO2aX;uJGF{e2G7 NVTEcokyOi53L{WvNVAh|ryP NYnDc2o2OC53IHi= MXzicI9kc3NiSVfGMWlKNWmwZIXj[YQhW1SVIH3SUmEh\XiycnXzd4lwdsLi NVPsdGhkOjRyNUW1NlA>
THP-1  M1vKcWZ2dmO2aX;uJGF{e2G7 MXKxNOKh|ryP MV[xxsBp NHG4OY9i[m:uaYPo[ZMhfGinIHXm[oVkfCCxZjDyTHNROjdib36gV3IuSSCvUl7B NIfHeIgzOzl|OUO5PC=>
A549 MV3GeY5kfGmxbjDBd5NigQ>? M17wdFHDqM7:TR?= MWe0PEBp NF3iPHNmdmijbnPld{B1cGVidYCtdoVofWyjdHnvckBw\iCLzsrCJIFv\CC|dXLz[ZF2\W62IHTlZ5Jm[XOnIHnuJGJigCCneIDy[ZN{cW:wIHnu[JVk\WRiYomgZ49u[mmwZXSgd5RqdXWuYYTpc44> M{nRcFI{QTByMEiw
A549 MX7BdI9xfG:|aYOgRZN{[Xl? NITMNo8yyqEQvF2= NUL0Z3VsPDhiaB?= M3TSUZJm\HWlZYOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTDjc41jcW6nZDDzeIlufWyjdHnvci=> MkG3NlM6ODByOEC=
NCI-N87 Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWqxNE8zOC9|MDFOwG0> NYO3RZVDPi9{NDDo MlzNd5VxeHKnc4Pld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NFrReHAzOzh2NkW0OS=>
AGS MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\p[pMyOC9{MD:zNEDPxE1? MXq2M|I1KGh? NFi0RYh{fXCycnXzd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NEPXdXozOzh2NkW0OS=>
MGC80-3 NYLFcGZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDFO4oyOC9{MD:zNEDPxE1? MYW2M|I1KGh? NV;aO5J5e3WycILld5NmeyClZXzsJJZq[WKrbHn0fUB{cWewaX\pZ4FvfGy7 NGnhW28zOzh2NkW0OS=>
HGC-27  M1TmUWZ2dmO2aX;uJGF{e2G7 NV;hZ5kxPy53L{G1M|MxKM7:TR?= NXjMVYFOPiCq Mm\BbY5lfWOnczD0bIUh\GWyaH;zdIhwenmuYYTpc44h[W6mIIXwMZJm\3WuYYTpc44hd2ZiSd86Ru6y Mnn5NlM5PDZ3NEW=
MGC80-3 NXewS215TnWwY4Tpc44hSXO|YYm= MoDQO{42NzF3L{OwJO69VQ>? NVnYT2hOPiCq MWTpcoR2[2W|IITo[UBl\XCqb4PwbI9zgWyjdHnvckBidmRidYCtdoVofWyjdHnvckBw\iCLzsrC{tE> NETEPWczOzh2NkW0OS=>
HGC-27  MX3BdI9xfG:|aYOgRZN{[Xl? NWG1T|lsPy53L{G1M|MxKM7:TR?= M{izZVYhcA>? M4DLPYlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NH:3eYwzOzh2NkW0OS=>
HBE  M2TNTGZ2dmO2aX;uJGF{e2G7 M3vyOVEx|ryP MonkN4g> NEXNUG5i[m:uaYPo[ZMhfGinIHnuZ5Jm[XOnczDv[kBKVC14IHX4dJJme3Orb36gbY5lfWOnZDDifUBEW0V? NHfERo0zOzh{NEC4PS=>
HepG2 NX[5XJY3TnWwY4Tpc44hSXO|YYm= NID4[5ExNjNxMT:zJO69VQ>? M3XBZVQ5KGh? NVfHUYM6emWmdXPld{BKVDZvaX7keYNm\CCST16xJIV5eHKnc4Ppc44> NVva[2tKOjN5OUG4N|M>
THP-1 M1;ibmZ2dmO2aX;uJGF{e2G7 NUTkWoR{PSEEtV2= MkH3NUBp M4LiT2ROW09? M3XGb4lvcGmkaYTzJG1VSi2rbnT1Z4VlKE6IzsrCJIFkfGm4YYTpc44> M{TMU|I{PjN2MkG4
THP-1  MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnuNXc2KML3TR?= NIL5O5I1NzhiZB?= NUjHNJd2TE2VTx?= NEnsPG5z\WS3Y3XzJJRp\SC4aXHibYxqfHlib3[gbY51emGlZXzseYxiesLiTWTC NYLJNFlZOjN4M{SyNVg>
MDM MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfoOUDDvU1? MWC0M|gh\A>? Mmj1SG1UVw>? MnWzdoVlfWOnczD0bIUhfmmjYnnsbZR6KG:oIHnueJJi[2WubIXsZZLDqE2WQh?= NX\BcJhUOjN4M{SyNVg>
AM MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVK1JOK2VQ>? NWnLc2QyPC96IHS= NIPaT2lFVVOR Mn7sdoVlfWOnczD0bIUhfmmjYnnsbZR6KG:oIHnueJJi[2WubIXsZZLDqE2WQh?= MXuyN|Y{PDJzOB?=
RAW 264  M1S3V2Z2dmO2aX;uJGF{e2G7 NVXTUVl6OC5{LUWgxtVO NFjEVZo{OC94MD:5NEBucW5? MmXpbY5pcWKrdIOgeIhmKHCqb4PwbIF1[XOnIHHjeIl3cXS7IH;mJHBVWDGEwrC= NXrTPGFqOjN3N{izNFI>
HUVEC NFr3bZlHfW6ldHnvckBCe3OjeR?= M4XBV|ExyqEQvF2= MX:wMlUhcA>? MV;EUXNQ MXfjc5VvfGW{YXP0[ZMhfGinIHzvd5Mhd2ZiVHnlNkBuWk6D NHTRTY4zOzV4M{[zNi=>
HT29 M4T4VmZ2dmO2aX;uJGF{e2G7 NHLHPGgyOC9|MD:xNFAh|ryP MV:xJIg> MUTpcohq[mm2ZYOgZo91cCCWV1XBT{1qdmS3Y3XkJJAyODBicILvZ4V{e2mwZx?= NHHUOIMzOzV{N{G1OC=>
HT29 NGrZNm1HfW6ldHnvckBCe3OjeR?= M4ixOFExNzNyL{GwNEDPxE1? M1X2T|EhcA>? Mlv3bY5pcWKrdIOgWG5HNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJIFv\CCmZXfyZYRifGmxbjDv[kBK|rqEzsG= M2izOFI{PTJ5MUW0
MM.1S M2O3[WFxd3C2b4Ppd{BCe3OjeR?= NXjDfVM6OzBiwsXN MXezJIg> MYHpcoR2[2W|IF3NJINmdGxiZHXheIghcW64b3z2[ZMhdmWlcn;zbZM> MkLHNlM2OjdzNUS=
KMS-12-BM M2n2OWFxd3C2b4Ppd{BCe3OjeR?= MnPSN|AhyrWP NH;XTpI{KGh? NH;1UoNqdmS3Y3XzJG1OKGOnbHyg[IVifGhiaX72c4x3\XNibnXjdo9{cXN? NInXOWgzOzV{N{G1OC=>
BAFs MVPGeY5kfGmxbjDBd5NigQ>? NH7LeosxNjVxMdMg{txO NWrqNZExOjRiaB?= MWHpcohq[mm2czDUUmbPuS:GRWigbY5lfWOnZDDDXXAyQUFzwrD0doFve2O{aYD0dy=> Mn\YNlM1QDV2NUe=
SP6.5 Ml3mSpVv[3Srb36gRZN{[Xl? MkHjOUDPxE1? NI[1NI4zKGh? NYDXPHVz\GWlcnXhd4V{yqC2cnHud4xw[2G2aX;uJI9nKHB4NTDpckB1cGViboXjcIV2e8Li NGm0VGEzOzR2M{C4Oi=>
VUP MkLFSpVv[3Srb36gRZN{[Xl? NGDWTGc2KM7:TR?= NEiySG4zKGh? NYPG[FhN\GWlcnXhd4V{yqC2cnHud4xw[2G2aX;uJI9nKHB4NTDpckB1cGViboXjcIV2e8Li MYKyN|Q1OzB6Nh?=
OCM1 M1;PNmZ2dmO2aX;uJGF{e2G7 M2Xle|Uh|ryP M2DPN|IhcA>? MnHx[IVkemWjc3XzxsB1emGwc3zvZ4F1cW:wIH;mJJA3PSCrbjD0bIUhdnWlbHX1d:Kh MWOyN|Q1OzB6Nh?=
OM431 M2\rUWZ2dmO2aX;uJGF{e2G7 NHXUZmU2KM7:TR?= NGrHWWQzKGh? Mk\P[IVkemWjc3XzxsB1emGwc3zvZ4F1cW:wIH;mJJA3PSCrbjD0bIUhdnWlbHX1d:Kh NXro[nh5OjN2NEOwPFY>
SP6.5 MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXkNk42NTJyIN88US=> MXKyOEBpyqB? M3f6fGlEPTB;NTFOwG0tKGW6aHnibZR{KHO2cn;u[{BidnSrLYDyc4xq\mW{YYTpeoUh\W[oZXP0d{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MoP1NlM1PDNyOE[=
VUP M3PPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPGNJF7Oi53LUKwJO69VQ>? NUXuWXJMOjRiaNMg NUO4XIVRUUN3ME21JO69VSxiZYjobYJqfHNic4Tyc45oKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5R{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MlvLNlM1PDNyOE[=
OCM1 M333e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILyPHMzNjVvMkCg{txO MlK0NlQhcMLi NX7FWJdTUUN3ME21JO69VSxiZYjobYJqfHNic4Tyc45oKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5R{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NY[1TlJvOjN2NEOwPFY>
OM431 M{\Wfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmyMlUuOjBizszN M3LFVlI1KGkEoB?= MnvuTWM2OD13IN88UUwh\XiqaXLpeJMhe3S{b37nJIFvfGlvcILvcIln\XKjdHn2[UBm\m[nY4TzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MljONlM1PDNyOE[=
SP6.5 NGm1[5ZCeG:ydH;zbZMhSXO|YYm= NIDmSXI2KM7:TR?= MXSyOEBpyqB? NUnacmFvcW6mdXPld{BieG:ydH;zbZPDqA>? M{fyR|I{PDR|MEi2
VUP MnfURZBweHSxc3nzJGF{e2G7 Ml7zOUDPxE1? MofwNlQhcMLi MXXpcoR2[2W|IHHwc5B1d3Orc9Mg NWrie2JHOjN2NEOwPFY>
OCM1 NFT5bFhCeG:ydH;zbZMhSXO|YYm= MkjCOUDPxE1? NEWy[5kzPCCqwrC= MUTpcoR2[2W|IHHwc5B1d3Orc9Mg M4C3d|I{PDR|MEi2
OM431 NVq4XmhvSXCxcITvd4l{KEG|c3H5 Mn\0OUDPxE1? NGjUPFMzPCCqwrC= NXW2SYI2cW6mdXPld{BieG:ydH;zbZPDqA>? MofPNlM1PDNyOE[=
SP6.5 M2fkPGZ2dmO2aX;uJGF{e2G7 MUm1JO69VQ>? MmjUNVIhcA>? MnPLdoVlfWOnczD0bIUhdWmpcnH0bY9vyqB? NUn1dHV1OjN2NEOwPFY>
VUP NE\n[ZJHfW6ldHnvckBCe3OjeR?= M3TXVVUh|ryP NVKxPYd1OTJiaB?= NIS4TpRz\WS3Y3XzJJRp\SCvaXfyZZRqd28EoB?= NITyN2MzOzR2M{C4Oi=>
OCM1 Mn7sSpVv[3Srb36gRZN{[Xl? MXK1JO69VQ>? M4PMRlEzKGh? NEjQfZRz\WS3Y3XzJJRp\SCvaXfyZZRqd28EoB?= MYCyN|Q1OzB6Nh?=
OM431 NXznSoV6TnWwY4Tpc44hSXO|YYm= M{HyXlUh|ryP NUjiW2VHOTJiaB?= MYLy[YR2[2W|IITo[UBucWe{YYTpc47DqA>? MXOyN|Q1OzB6Nh?=
HBL-1  M2nGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrNR4ZwO8LizszN M{PNeVI1NzR6L{eyJIg> NYiwXHZwTE2VTx?= M4DkfZNtd3e|IHPlcIwh\3Kxd4ToJI1w\GW|dHz5 MYGyN|Q1OTd|MB?=
RAW 264.7 M1WwZ2Z2dmO2aX;uJGF{e2G7 NV;RSlFVOi1zNTFOwG0> NX7x[XZGOSCq M1LCRWROW09? NGTrWJd{fXCycnXzd4V{KHSqZTDhZ5RqfmG2aX;uJI9nKEmNSzDmZY1qdHlibXXtZoVzew>? M1fse|I{PDRzN{Ow
IL-1R  MV;GeY5kfGmxbjDBd5NigQ>? NUTnUFhqOi1zNTFOwG0> MWKxJIg> MYjEUXNQ NWLSd2tje3WycILld5NmeyC2aHWgZYN1cX[jdHnvckBw\iCLS1ug[oFucWy7IH3lcYJmenN? M1PrbFI{PDRzN{Ow
RAW 264.7 NEfXeIhHfW6ldHnvckBCe3OjeR?= Mn[4NVUh|ryP NYTSOlRsOSCq NU\2dI13TE2VTx?= NXzVNHB{e3WycILld5NmeyC2aHWgZYN1cX[jdHnvckBw\iCjbnSgTm5M NULD[VdSOjN2NEG3N|A>
IL-1R  M{PDNWZ2dmO2aX;uJGF{e2G7 M1r1SFE2KM7:TR?= M2DkVVEhcA>? NWjTcGVGTE2VTx?= MkfId5VxeHKnc4Pld{B1cGViYXP0bZZifGmxbjDv[kBidmRiSl7L NHraO5QzOzR2MUezNC=>
U2OS NF;jNFVHfW6ldHnvckBCe3OjeR?= M4\yZVE2KM7:TR?= NYn0[IE6OSCq MmPvSG1UVw>? NWLxZlRLeHKndnXueJMhfGinIFzQV{0hd3JiSVytNU1{fGmvdXzheIVlKG[xcn3heIlwdiCxZjDLOlMueFWkIHPoZYlve8Li MnLaNlM1PDF5M{C=
MT‐1  NGnhOHhHfW6ldHnvckBCe3OjeR?= MWO4xsDDvW1? M3nHZlMhcA>? MnT4[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicPMAlHNVSVR|IHHu[EBx6oDSNFXCVFE> M3Px[|I{Ojd6NEe5
MT‐2  M1HaU2Z2dmO2aX;uJGF{e2G7 NFnEO205yqEEtX2= MlS2N{Bp NFXkU2xl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDw5qCRW1SDVEOgZY5lKHEkgKC0SWJROQ>? M1TsNlI{Ojd6NEe5
MT‐1  M{jOdmZ2dmO2aX;uJGF{e2G7 MWW4xsDDvW1? NYXiV|hVOyCq M2e3XYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBxPjVic4XieY5qfCCxZjDOSwKBmM78QtMg MnXINlMzPzh2N{m=
MT‐2  NHrud21HfW6ldHnvckBCe3OjeR?= MmrMPOKhyrWv MnTTN{Bp M{DkfIRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBxPjVic4XieY5qfCCxZjDOSwKBmM78QtMg MYOyN|I4QDR5OR?=
MCF-7  MWTGeY5kfGmxbjDBd5NigQ>? NESwT5gzNjVvMUWg{txO NIrFUYUxNjViaB?= NW[3R2dETE2VTx?= MnP2Z4F2e2W|IITo[UBoemGmdXHsJIxwe3Nib3[gZ4VtdCCjZHjld4lwdg>? MVuyN|A6OzJ{Nx?=
HaCaT  MYfGeY5kfGmxbjDBd5NigQ>? MkXPOU4xyqEQvF2= MkL6NeKhcMLi MWLheJRmdnWjdHXzJJRp\SCWQ1;IMYlv\HWlZXSgdJJw\HWldHnvckBw\iCLTD22xsA> MlLaNlMxPDFzNki=
A549  NXu1[|VUTnWwY4Tpc44hSXO|YYm= Mn3FNUBp MlfabY5pcWKrdIOgUHRCNWmwZIXj[YQhW1BvQTDtVm5CKHC{b3T1Z5Rqd28EoIPp[45q\mmlYX70cJk> MoPENlMxOzF{MUO=
OA chondrocytes  NVnJXlNXTnWwY4Tpc44hSXO|YYm= NITUfGoyOCEQvF2= MVqxJIg> M3LUd4Jtd2OtczD0bIUhSUeHLVLTRU1qdmS3Y3XkJIdmdmVxcILveIVqdiCneIDy[ZN{cW:wIH;mJGdTWDd6IH;yJGNQYC1{IDjwQFAvODVr MWmyNlk5OjJ{OB?=
RAW264.7 MXXGeY5kfGmxbjDBd5NigQ>? MWmxOUDPxE1? MVSxOU0yOjBibXnu NUiyW4xs[myxY3vzJJRp\SCycn;keYN1cW:wIH;mJG5QNCCSR1WyMEBidmRiVF7GMe6y MkXYNlI4PDV3MkO=
RAW264.7 NI\KVGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[2SFUuOzBizszN MXWyOEBp NX;ObW1McW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2\YR|IzPzR3NUKz
HBL6 NIHB[5NCeG:ydH;zbZMhSXO|YYm= NX3iO49zOC53L{WvNlUh|ryP M2Gw[VYwOjRiaB?= MUDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliYX7kJIxm\WGmczD0c{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? MnfDNlIxPzR6MkC=
HT29  M{LTRmZ2dmO2aX;uJGF{e2G7 NWKwbXdtOS1zMDFOwG0> MmjSNVDDqGh? NGHPOIdqdmO{ZXHz[ZMhUE9vMTDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= MUeyNVYzODl4NB?=
Ca9–22 MWjBdI9xfG:|aYOgRZN{[Xl? M{jQO|ExyqEQvF5CpC=> MVixJIg> M2L1NoNwdXCuZYTlcJkhcW6qaXLpeJMhSUyDLWDEWE1qdmS3Y3XkJIFxd3C2b4Ppdy=> MX:yNVE{QDR6MB?=
Ca9–22 NYO4e456TnWwY4Tpc44hSXO|YYm= M{P3c|ExyqEQvF5CpC=> NHvxOWcyKGh? NUXxdIpm[2:vcHzleIVtgSCjYoLv[4F1\XNidHjlJGFNSS2SRGStbY5lfWOnZDDKUmsh[WO2aY\heIlwdg>? Mn7xNlEyOzh2OEC=
A-549 M4nBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37yVVExyqEQvF5CpC=> M3fYeFI1NzR6IHi= MV3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NWP5elR5OjB6Nk[wOFM>
AP NU[4bmlTTnWwY4Tpc44hSXO|YYm= MmjNOU8yOCEQvF2= MUm0PEBp NULvU2ZG\G:5boLl[5Vt[XSnczD0bIUhSkGGIIDyc5RmcW5ibHX2[Ywh[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NX3uPWNGOjB3OU[2OFU>
AQ1 M3q5XGZ2dmO2aX;uJGF{e2G7 NF;5[Wo2NzFyIN88US=> NF7pTFk1QCCq M{nSb4Rwf26{ZXf1cIF1\XNidHjlJGJCTCCycn;0[YlvKGyndnXsJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NFG2fHczODV7Nk[0OS=>
AP M{DjTWZ2dmO2aX;uJGF{e2G7 NHS4ZlMzOCEQvF2= NIXucJc1NzhiaB?= MWPkc5dvemWpdXzheIV{KHSqZTDCRWQheHKxdHXpckBt\X[nbDDhJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M13ST|IxPTl4NkS1
AQ1 NGqyWYFHfW6ldHnvckBCe3OjeR?= MmPZNlAh|ryP NUfnRYFYPC96IHi= M4PqN4Rwf26{ZXf1cIF1\XNidHjlJGJCTCCycn;0[YlvKGyndnXsJIEhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NG\3SWQzODV7Nk[0OS=>
THP-1 MUXGeY5kfGmxbjDBd5NigQ>? M332cFXDqM7:TdMg NV3qTndWOC53IHi= NE\OWmRifHSnboXheIV{KHSqZTDMVHMucW6mdXPl[EBxNUoQulNOtUBxem:2ZXnuJIJ6KDd{JR?= M4WyZ|IxOzB7N{G4
K562 NHHhcYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSyMVMxKM7:TR?= M3PidVI1KGh? M1vmfWlEPTB;ODFOwG0tcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3iyWVE6PjR4OEC3
Jurket NYfUXXNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;USZgzNTNyIN88US=> NYPOOYdXOjRiaB?= Mn7wTWM2OD15LkGg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFLRWXcyQTZ2NkiwOy=>
U937 NYjKc2k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1noN|IuOzBizszN NY\WV2Q1OjRiaB?= MljGTWM2OD1zMD61JO69VSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MWGxPVY1PjhyNx?=
PBMC NXXseFFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD6PJEzNTNyIN88US=> NIXGdpgzPCCq NGDxb2ZKSzVyPUSwMlIh|ryPLDDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NXX6ZVNFOTl4NE[4NFc>
K562 MVzBdI9xfG:|aYOgRZN{[Xl? NILye|czNTJywrFOwG3DqA>? NWnsN|dyOjRiaB?= MlzRbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHHwc5B1d3Orcx?= NFH2NJoyQTZ2NkiwOy=>

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: NCI-H1703 cells
  • Concentrations: ~8 μM
  • Incubation Time: 12 hours
  • Method: Cells are transfected with siRNA in 96-well microtiter plates and then cultured for 72 hours in complete NSCLC medium, treated with BAY 11-7082 for 12 hours. Cells are incubated with [3H]thymidine for 3 hours. The cells are collected on filters using an automatic cell harvester and radioactivity on the filters is measured by β-scintillation counting.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 41 mg/mL (197.82 mM)
Ethanol 10 mg/mL (48.25 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 207.25
Formula

C10H9NO2S

CAS No. 19542-67-7
Storage powder
in solvent
Synonyms BAY 11-7821

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IκB/IKK Signaling Pathway Map

IκB/IKK Inhibitors with Unique Features

Related IκB/IKK Products4

Tags: buy BAY 11-7082 | BAY 11-7082 supplier | purchase BAY 11-7082 | BAY 11-7082 cost | BAY 11-7082 manufacturer | order BAY 11-7082 | BAY 11-7082 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID